Publications by authors named "Matthias Gehringer"

Claim this Profile
A
A twist in the tale: shifting from covalent targeting of a tyrosine in JAK3 to a lysine in MK2.
Laura Hillebrand, Guiqun Wang, Alexander Rasch, Benedikt Masberg, Apirat Chaikuad, Matthias Gehringer

RSC Med Chem· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Go for Gold: Development of a Scalable Synthesis of [1-(Ethoxycarbonyl)cyclopropyl] Triphenylphosphonium Tetrafluoroborate, a Key Reagent to Explore Covalent Monopolar Spindle 1 Inhibitors.
Leon Rebhan, Rebekka Fürst, Dieter Schollmeyer, Ricardo A M Serafim, Matthias Gehringer

ChemistryOpen· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective ubiquitination of drug-like small molecules by the ubiquitin ligase HUWE1.
Barbara Orth, Pavel Pohl, Florian Aust, Yanlong Ji, Ayshwarya Seenivasan, Matthias Gehringer

Nat Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Warm Welcome to MedChem: The Frontiers in Medicinal Chemistry 2025.
Matthias Schiedel, Marta Pinto, Andrea Unzue Lopez, Philipp Barbie, Felix Pape, Matthias Gehringer

ChemMedChem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, Synthesis, and Molecular Evaluation of SAr-Reactive N-(6-Fluoro-3-Nitropyridin-2-yl)Isoquinolin-3-Amines as Covalent USP7 Inhibitors Reveals an Unconventional Binding Mode.
Larissa N Ernst, Jason Stahlecker, Finn Mier, Ricardo A M Serafim, Valentin R Wydra, Matthias Gehringer

Arch Pharm (Weinheim)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Quality In Vivo Chemical Probes for Protein Kinases Disclosed in 2024.
Ricardo A M Serafim, Matthias Gehringer

ACS Pharmacol Transl Sci· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening of Covalent Kinase Inhibitors Yields Hits for Cysteine Protease USP7 / HAUSP.
Larissa N Ernst, Simon J Jaag, Valentin R Wydra, Benedikt Masberg, Cornelius Knappe, Matthias Gehringer

Drug Des Devel Ther· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Probing the Protein Kinases' Cysteinome by Covalent Fragments.
Guiqun Wang, Nico J Seidler, Sandra Röhm, Yufeng Pan, Xiaojun Julia Liang, Matthias Gehringer

Angew Chem Int Ed Engl· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
We are MedChem: The Frontiers in Medicinal Chemistry 2024.
Matthias Schiedel, Philipp Barbie, Felix Pape, Marta Pinto, Andrea Unzue Lopez, Matthias Gehringer

ChemMedChem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demystifying Functional Parameters for Irreversible Enzyme Inhibitors.
David E Heppner, Blessing C Ogboo, Daniel A Urul, Earl W May, Erik M Schaefer, Matthias Gehringer

J Med Chem· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a Covalent Library of Diverse Warheads (CovLib) Binding to JNK3, USP7, or p53.
Theresa Klett, Martin Schwer, Larissa N Ernst, Marc U Engelhardt, Simon J Jaag, Matthias Gehringer

Drug Des Devel Ther· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Lewy body dementia with neflamapimod-rasagiline hybrids.
Claudia Albertini, Sabrina Petralla, Francesca Massenzio, Barbara Monti, Nicola Rizzardi, Matthias Gehringer

Arch Pharm (Weinheim)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.
Laura Hillebrand, Xiaojun Julia Liang, Ricardo A M Serafim, Matthias Gehringer

J Med Chem· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of Highly Potent and Selective Covalent FGFR4 Inhibitors Based on SAr Electrophiles.
Moritz Schwarz, Maksym Kurkunov, Florian Wittlinger, Ramona Rudalska, Guiqun Wang, Matthias Gehringer

J Med Chem· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Collection: Drug Discovery in Germany.
Stefan Laufer, Matthias Gehringer, Alexander Titz

J Med Chem· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Covalent Inhibitors in Drug Discovery, Chemical Biology and Beyond.
Ricardo A M Serafim, Matthias Gehringer, Chiara Borsari

Pharmaceuticals (Basel)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Back in Person: Frontiers in Medicinal Chemistry 2023.
Matthias Gehringer, Felix Pape, María Méndez, Philipp Barbie, Andrea Unzue Lopez

ChemMedChem· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frontiers in Medicinal Chemistry 2022 Goes Virtual.
Eleonora Diamanti, María Méndez, Tatjana Ross, Christian A Kuttruff, Julien Lefranc, Matthias Gehringer

ChemMedChem· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Publication Criteria and Requirements for Studies on Protein Kinase Inhibitors─What Is Expected?
Stefan Laufer, Jürgen Bajorath, Matthias Gehringer, Nathanael Gray, Stephen Frye

J Med Chem· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Never Gonna Give You Up - Current Developments in Covalent Protein Kinase Inhibitors.
Laura Hillebrand, Matthias Gehringer

Chimia (Aarau)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer.
Carine M Abdelmalek, Zexi Hu, Thales Kronenberger, Jenni Küblbeck, Franziska J M Kinnen, Matthias Gehringer

J Med Chem· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor.
Ricardo A M Serafim, André da Silva Santiago, Martin P Schwalm, Zexi Hu, Caio V Dos Reis, Matthias Gehringer

J Med Chem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chemical Probes for Understudied Kinases: Challenges and Opportunities.
Ricardo A M Serafim, Jonathan M Elkins, William J Zuercher, Stefan A Laufer, Matthias Gehringer

J Med Chem· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent and Highly Isoform-Selective Inhibitor of the Neglected Ribosomal Protein S6 Kinase Beta 2 (S6K2).
Stefan Gerstenecker, Lisa Haarer, Martin Schröder, Mark Kudolo, Martin P Schwalm, Matthias Gehringer

Cancers (Basel)· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.
Cláudia Monfroni Rocha, Alessandro Menna Alves, Beatriz Fabris Bettanin, Fernanda Majolo, Matthias Gehringer

Inflammopharmacology· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis